Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia

Anikó Barta, Róbert Dénes, T. Masszi, Péter Reményi, Árpád Bátai, Éva Torbágyi, Andrea Sipos, Lilla Lengyel, Katalin Jakab, Éva Gyódi, Marienn Réti, János Földi, Piroska Páldi-Haris, Manuel Avalos, K. Pálóczi, Sándorné Fekete, Judit Török, Izabella Hoffer, Judit Jakab, Gábor VáradiEndre Kelemen, G. Petrányi

Research output: Article

13 Citations (Scopus)

Abstract

A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from sibling donors. Risk factors include: accelerated phase (10 patients), older age (17 patients over>40 years) and long interval between diagnosis and BMT (27 months on average). Severe mucositis did not occur. Venoocclusive liver disease was absent. Infectious complications were rare. Although grade II-IV acute graft-versus-host disease (GVHD) was present in 9 (25%) cases, there were only 2 serious (III-IV) ones. Chronic GVHD occurred in 25 (69%) cases, preceded by acute GVHD in 9 of the 25 affected patients. Early hematological relapse, 7-29 weeks after BMT, developed in 6 patients (17.6%). No relapse was noted in the completely chimeric patients, however molecular genetic residual disease was observed in 6 patients, in most of them after transient short-term mixed chimeric state. Overall actual survival rate is 83.3% for the 36 cases, and leukemia-free survival is 72.2% for the 34 engrafted patients.

Original languageEnglish
Pages (from-to)64-70
Number of pages7
JournalActa Haematologica
Volume105
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Mitobronitol
Homologous Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Transplants
Graft vs Host Disease
Recurrence
Inborn Genetic Diseases
Mucositis
Conditioning (Psychology)
Cytarabine
Cyclophosphamide
Liver Diseases
Siblings
Molecular Biology
Leukemia
Survival Rate

ASJC Scopus subject areas

  • Hematology

Cite this

Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. / Barta, Anikó; Dénes, Róbert; Masszi, T.; Reményi, Péter; Bátai, Árpád; Torbágyi, Éva; Sipos, Andrea; Lengyel, Lilla; Jakab, Katalin; Gyódi, Éva; Réti, Marienn; Földi, János; Páldi-Haris, Piroska; Avalos, Manuel; Pálóczi, K.; Fekete, Sándorné; Török, Judit; Hoffer, Izabella; Jakab, Judit; Váradi, Gábor; Kelemen, Endre; Petrányi, G.

In: Acta Haematologica, Vol. 105, No. 2, 2001, p. 64-70.

Research output: Article

Barta, A, Dénes, R, Masszi, T, Reményi, P, Bátai, Á, Torbágyi, É, Sipos, A, Lengyel, L, Jakab, K, Gyódi, É, Réti, M, Földi, J, Páldi-Haris, P, Avalos, M, Pálóczi, K, Fekete, S, Török, J, Hoffer, I, Jakab, J, Váradi, G, Kelemen, E & Petrányi, G 2001, 'Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia', Acta Haematologica, vol. 105, no. 2, pp. 64-70. https://doi.org/10.1159/000046536
Barta, Anikó ; Dénes, Róbert ; Masszi, T. ; Reményi, Péter ; Bátai, Árpád ; Torbágyi, Éva ; Sipos, Andrea ; Lengyel, Lilla ; Jakab, Katalin ; Gyódi, Éva ; Réti, Marienn ; Földi, János ; Páldi-Haris, Piroska ; Avalos, Manuel ; Pálóczi, K. ; Fekete, Sándorné ; Török, Judit ; Hoffer, Izabella ; Jakab, Judit ; Váradi, Gábor ; Kelemen, Endre ; Petrányi, G. / Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. In: Acta Haematologica. 2001 ; Vol. 105, No. 2. pp. 64-70.
@article{4888ccc166f1497f8ff4c4da0579689c,
title = "Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia",
abstract = "A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from sibling donors. Risk factors include: accelerated phase (10 patients), older age (17 patients over>40 years) and long interval between diagnosis and BMT (27 months on average). Severe mucositis did not occur. Venoocclusive liver disease was absent. Infectious complications were rare. Although grade II-IV acute graft-versus-host disease (GVHD) was present in 9 (25{\%}) cases, there were only 2 serious (III-IV) ones. Chronic GVHD occurred in 25 (69{\%}) cases, preceded by acute GVHD in 9 of the 25 affected patients. Early hematological relapse, 7-29 weeks after BMT, developed in 6 patients (17.6{\%}). No relapse was noted in the completely chimeric patients, however molecular genetic residual disease was observed in 6 patients, in most of them after transient short-term mixed chimeric state. Overall actual survival rate is 83.3{\%} for the 36 cases, and leukemia-free survival is 72.2{\%} for the 34 engrafted patients.",
keywords = "Allogeneic bone marrow transplantation, Bone marrow transplantation, complication, Chemotherapy, Chronic myeloid leukemia, Myelosuppressive conditioning, Transplantation",
author = "Anik{\'o} Barta and R{\'o}bert D{\'e}nes and T. Masszi and P{\'e}ter Rem{\'e}nyi and {\'A}rp{\'a}d B{\'a}tai and {\'E}va Torb{\'a}gyi and Andrea Sipos and Lilla Lengyel and Katalin Jakab and {\'E}va Gy{\'o}di and Marienn R{\'e}ti and J{\'a}nos F{\"o}ldi and Piroska P{\'a}ldi-Haris and Manuel Avalos and K. P{\'a}l{\'o}czi and S{\'a}ndorn{\'e} Fekete and Judit T{\"o}r{\"o}k and Izabella Hoffer and Judit Jakab and G{\'a}bor V{\'a}radi and Endre Kelemen and G. Petr{\'a}nyi",
year = "2001",
doi = "10.1159/000046536",
language = "English",
volume = "105",
pages = "64--70",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia

AU - Barta, Anikó

AU - Dénes, Róbert

AU - Masszi, T.

AU - Reményi, Péter

AU - Bátai, Árpád

AU - Torbágyi, Éva

AU - Sipos, Andrea

AU - Lengyel, Lilla

AU - Jakab, Katalin

AU - Gyódi, Éva

AU - Réti, Marienn

AU - Földi, János

AU - Páldi-Haris, Piroska

AU - Avalos, Manuel

AU - Pálóczi, K.

AU - Fekete, Sándorné

AU - Török, Judit

AU - Hoffer, Izabella

AU - Jakab, Judit

AU - Váradi, Gábor

AU - Kelemen, Endre

AU - Petrányi, G.

PY - 2001

Y1 - 2001

N2 - A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from sibling donors. Risk factors include: accelerated phase (10 patients), older age (17 patients over>40 years) and long interval between diagnosis and BMT (27 months on average). Severe mucositis did not occur. Venoocclusive liver disease was absent. Infectious complications were rare. Although grade II-IV acute graft-versus-host disease (GVHD) was present in 9 (25%) cases, there were only 2 serious (III-IV) ones. Chronic GVHD occurred in 25 (69%) cases, preceded by acute GVHD in 9 of the 25 affected patients. Early hematological relapse, 7-29 weeks after BMT, developed in 6 patients (17.6%). No relapse was noted in the completely chimeric patients, however molecular genetic residual disease was observed in 6 patients, in most of them after transient short-term mixed chimeric state. Overall actual survival rate is 83.3% for the 36 cases, and leukemia-free survival is 72.2% for the 34 engrafted patients.

AB - A non-myeloablative conditioning protocol containing dibromomannitol (DBM/cytosine arabinoside/cyclophosphamide) has been applied to 36 chronic myeloid leukemia (CML) patients followed by bone marrow transplantation (BMT) from sibling donors. Risk factors include: accelerated phase (10 patients), older age (17 patients over>40 years) and long interval between diagnosis and BMT (27 months on average). Severe mucositis did not occur. Venoocclusive liver disease was absent. Infectious complications were rare. Although grade II-IV acute graft-versus-host disease (GVHD) was present in 9 (25%) cases, there were only 2 serious (III-IV) ones. Chronic GVHD occurred in 25 (69%) cases, preceded by acute GVHD in 9 of the 25 affected patients. Early hematological relapse, 7-29 weeks after BMT, developed in 6 patients (17.6%). No relapse was noted in the completely chimeric patients, however molecular genetic residual disease was observed in 6 patients, in most of them after transient short-term mixed chimeric state. Overall actual survival rate is 83.3% for the 36 cases, and leukemia-free survival is 72.2% for the 34 engrafted patients.

KW - Allogeneic bone marrow transplantation

KW - Bone marrow transplantation, complication

KW - Chemotherapy

KW - Chronic myeloid leukemia

KW - Myelosuppressive conditioning

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=17844371044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844371044&partnerID=8YFLogxK

U2 - 10.1159/000046536

DO - 10.1159/000046536

M3 - Article

C2 - 11408706

AN - SCOPUS:17844371044

VL - 105

SP - 64

EP - 70

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2

ER -